Oppenheimer Resumes Coverage on BioSante Pharmaceuticals (BPAX) with an Outperform
More News related to BPAX
- BioSante Pharmaceuticals to Present at the Lazard Capital Markets Annual Healthcare Conference
- BioSante Pharmaceuticals Comments on Boehringer Ingelheim Clinical Test Results in Treatment of Female Sexual Dysfunction
- BioSante Pharmaceuticals to Present at Merriman Curhan Ford's Investor Summit
- BioSante Pharmaceuticals Reports Third Quarter 2009 Financial Results
- Rodman and Renshaw Initiates Coverage on Biosante Pharmaceuticals (BPAX) with an Outperform
More News related to New Coverage
- United Community Financial (UCFC) and United Bancshares (UBOH) To Sell Findlay, OH Branch to The Union Bank Co.
- GE receives French notice that its Areva bid wasn't chosen
- Health Management Associates (HMA) Completes Acquisition of Sparks Health System
- Wright Medical (WMGI) Reports Favorable Ruling in Stryker (SYK) Patent Infringement Case
- United Rentals (URI) Awarded Purchasing Contracts in Massachusetts and Texas
Oppenheimer resumes coverage on BioSante Pharmaceuticals (Nasdaq: BPAX) with an Outperform rating. Price target $6.
To see more analyst ratings on BPAX Click Here.
BioSante Pharmaceuticals, Inc., a biopharmaceutical company, develops products for female sexual health, menopause, contraception, and male hypogonadism.
Related Categories
New CoverageStocks Mentioned
-0.04Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
